Gepirone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gepirone
Gepirone.svg
Systematic (IUPAC) name
4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
Clinical data
  • Uncontrolled
Oral
Pharmacokinetic data
Half-life 2-3 hours
Identifiers
83928-76-1
N06AX19
PubChem CID 55191
ChemSpider 49836 YesY
UNII JW5Y7B8Z18 YesY
ChEMBL CHEMBL284092 YesY
Chemical data
Formula C19H29N5O2
359.46586 g/mol
 YesY (what is this?)  (verify)

Gepirone (Ariza, Variza; BMY-13,805, ORG-13,011) is an antidepressant and anxiolytic of the azapirone class. Like other azapirones, it acts as a selective partial agonist of the 5-HT1A receptor. Gepirone was under development in the U.S. in an extended release form, but despite completing phase III clinical trials, it failed to pass the drug approval process. As a result, gepirone, despite already having brand names picked out, did not manage to reach the pharmaceutical market.

Gepirone was originally developed by Bristol-Myers Squibb, but was out-licensed to Fabre-Kramer in 1993. The U.S. Food and Drug Administration (FDA) rejected approval for gepirone in 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2004. However, in 2007 it once again failed to convince the FDA of its qualities for treating anxiety and depression. There have been no updates on gepirone since.

Synthesis[edit]

Gepirone synth.png

Ormaza, V. A.; 1986, ES 8606333 .

See also[edit]

References[edit]